ViroMissile appoints Michael Wood as chief business officer

San Diego, USA-based ViroMissile has announced the appointment of Michael Wood as chief business officer (CBO). In this role, Mr Wood will lead ViroMissile’s corporate strategy, fundraising, and partnering activities as the company advances its proprietary IDOV platform toward key clinical and strategic milestones.

“Michael has repeatedly demonstrated the ability to translate innovative science into well-structured, well-capitalized biotechnology companies,” said Nanhai George Chen, founder and chief executive of ViroMissile, adding: “His leadership across fundraising, building teams and business development significantly strengthens our management team as we execute on our mission to deliver systemically administered oncolytic virus therapies for patients with difficult-to-treat cancers.”

Mr Wood brings more than three decades of experience spanning biotechnology, large pharmaceutical companies, investment banking, management consulting, and scientific research, with deep expertise in corporate strategy, fundraising, business development, and operational scale-up. He has played a key role in building and advancing multiple venture-backed and public biopharmaceutical companies from early formation through clinical-stage development and capital markets readiness to successful commercial launches.